Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment.
Quantitative measurement of SARS-CoV-2 neutralizing antibodies is highly expected to evaluate immune status, vaccine response, and antiviral therapy. The Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) was developed to measure anti-SARS-CoV-2 S proteins. We sought to investigate whether Elecsys® anti-S...
Main Authors: | Satomi Takei, Tomohiko Ai, Takamasa Yamamoto, Gene Igawa, Takayuki Kanno, Minoru Tobiume, Makoto Hiki, Kaori Saito, Abdullah Khasawneh, Mitsuru Wakita, Shigeki Misawa, Takashi Miida, Atsushi Okuzawa, Tadaki Suzuki, Kazuhisa Takahashi, Toshio Naito, Yoko Tabe |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0274181 |
Similar Items
-
Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment
by: Satomi Takei, et al.
Published: (2022-01-01) -
Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
by: Toshihiro Takahashi, et al.
Published: (2023-01-01) -
Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination
by: Toshihiro Takahashi, et al.
Published: (2023-01-01) -
Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
by: Maika Takahashi, et al.
Published: (2022-09-01) -
The Androstenedione Roche Elecsys immunoassay has superior comparability to the LC-MS/MS assay than the Siemens Immulite immunoassay
by: Ruhan Wei, et al.
Published: (2022-08-01)